E. R. Squibb Sons, Inc.

Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Bristol-myers Squibb Compnay

Medarex Inc.

N.v. Organon

Glaxosmithkline Biologicals Sa

Kent B Thudium

Alan J Korman

Mark J Selby

Heidi N Leblanc

Michael Houghton

Mohan Srinivasan

Nils Lonberg

Arvind Rajpal

Mark Yamanaka

Kyra D Zens

George Kuo

John Andrew Hall

Frank I Marcus

Robert O Ralston

Barbara A Gervase

Kim M Berger

Qui-Lim Choo

Edward L Halk

John M Polo

Silvia Perri

Han Chang

Thomas D Kempe

Susan Chien-Szu Wong

Timothy W Sproul

Marie-Michelle Navarro Garcia

Patrick Guirnalda

Dino Dina

Maria N Jure-Kunkel

Aaron Paul Yamniuk

Mark F Maurer

Xi-Tao Wang

Indrani Chakraborty

Andrea Van Elsas

Jennifer Marie Mataraza

Changyu Wang

Karla Ann Henning

Michelle Minhua Han

Alexander T Kozhich

Christina Maria Milburn

Kristopher Toy

Brenda L Stevens

Jochem Gokemeijer

Bryan C Barnhart

Michael Quigley

Xiang Shao

Lan Yang

Ming Lei

Liang Schweizer

Sandra V Hatcher

Hadia Lemar

Zhehong Cai

Zequn Tang

Praveen Aanur

Zheng Yang

Oui-Lim Choo

Christine Huang

Yan Feng

Maria Rodriguez

Sylvia Perri

The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to WIC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against OX-40 and uses thereof

Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereof

Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereof

Antibodies against OX40 and uses thereof

The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.

Fully human antibodies to BTLA

Chimeric alphavirus particles and alphavirus replicon RNAs are provided including methods of making and using same. The alphavirus replicon RNAs comprise deletions in one or more nonstructural proteins. Methods of making, using, and therapeutic preparations containing the chimeric alphavirus particle are disclosed.

Chimeric alphavirus replicon particles

Growing community of inventors

Oakland, CA, United States of America

Kent B Thudium